RESUMEN
Even with all of the new and old therapies available, seizure management is infamously difficult. Scientists will continue to search for novel drugs with high selectivity and low central nervous system side effects in the hopes of finding the newest and most effective treatment. This work designates the synthesis of several 4- quinazolinones substituted with oxadiazoles and benzothiazoles through condensation of 2-substituted-4H-benzo(1,3)-oxazin-4-ones with substituted-oxadiazole and 6-substituted-benzothiazol-2-amine. The title compounds were confirmed through IR, 1H-NMR, 13C-NMR analyses. The compounds evaluated for anticonvulsant activity. Compounds A3, A4, A9, A5, A10 possess good potential. They reduce the extent of tonic phase up to 1.3 to 1.1 seconds and stupor up to 100 to 51 seconds with absence of straub phase when compared to the control group.
RESUMEN
Anxiety is characterized by excessive fear that persists and interferes with a person's daily activities. In this study, a new class of 16 derivatives of 2-(Substituted Aryl)-piperazine-3-phenyl-4(3H)-quinazolinones were synthesized, and all of the derivatives were tested for their ability to reduce anxiety using the holeboard test and the elevated plus maize test, administered intraperitoneally to mice at doses of 10 mg/kg body weight. Test compounds 3-phenyl-2-(4-(3-methylphenyl) piperazin-1-yl)quinazolin-4(3H)-one (SD-05), 2-(4-(2-fluorophenyl) piperazin-1-yl)-3-phenylquinazolin-4(3H)-one (SD-06), 3-phenyl-2-(4-(4-methoxyphenyl) piperazin-1-yl)-quinazolin-4(3H)-one (SD-10) showed an increased number of head pocking (56 ± 3.5 to 70 ± 1) as compare to control group number of head pocking (27 ± 3) and increased duration of pocking (50 ± 12 ns) as compare to control group duration of pocking (25 ± 2) in hole board test and increased time spent in open arm (35.5 ± 1.5) and a number of entries in open arm (12.5 ± 0.50) as compare to control group. Test compounds SD-05, SD-06, SD-10 showed significant antianxiety activity.